(Q36573915)

15 August 2017

1 reference

title

Sertindole: efficacy and safety in schizophrenia (English)

1 reference

15 August 2017

1 reference

2

Sten Levander

1 reference

15 August 2017

Eva Lindström

1

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 September 2006

1 reference

Expert Opinion on Pharmacotherapy

15 August 2017

published in

1 reference

15 August 2017

volume

7

1 reference

15 August 2017

issue

13

1 reference

15 August 2017

page(s)

1825-1834

1 reference

Epidemiology of long-term functional psychosis in three different areas in Stockholm County

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1825

Variations in the incidence of schizophrenia: data versus dogma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1825

Atypical antipsychotics: Part II: Adverse effects, drug interactions, and costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1825

Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1825

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1825

The effect of neuroleptics on cognitive and psychomotor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1825

Smooth pursuit eye movements and neuropsychological impairments in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1825

Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1825

Tardive dyskinesia and antipsychotics: a 5-year longitudinal study of frequency, correlates and course

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1825

Higher cardiovascular mortality with sertindole in ADROIT: a signal not confirmed.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1825

Atypical antipsychotics: pharmacokinetics, therapeutic drug monitoring and pharmacological interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1825

A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1825

A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1825

Antipsychotic-related QTc prolongation, torsade de pointes and sudden death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1825

Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1825

Sertindole is a serotonin 5-HT2c inverse agonist and decreases agonist but not antagonist binding to 5-HT2c receptors after chronic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1825

In vivo effects on striatal dopamine D2 receptor binding by the novel atypical antipsychotic drug sertindole--a 123I IBZM single photon emission tomography (SPET) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1825

QTc interval prolongation and antipsychotic drug treatments: focus on sertindole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1825

Electrophysiological safety of sertindole in dogs with normal and remodeled hearts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1825

Effects of food, antacid, and dosage form on the pharmacokinetics and relative bioavailability of sertindole in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1825

Pharmacokinetics of sertindole in healthy young and elderly male and female subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1825

Atypical antipsychotics. Part I: Pharmacology, pharmacokinetics, and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1825

Sertindole (Serdolect): preclinical and clinical findings of a new atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1825

Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1825

Sertindole and dopamine D 2 receptor occupancy in comparison to risperidone, clozapine and haloperidol - a 123 I-IBZM SPECT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1825

Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1825

New generation versus conventional antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1825

A review of the efficacy, tolerability and safety of sertindole in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1825

Case histories illustrating the utility of sertindole in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1825

Five-component model of schizophrenia: Assessing the factorial invariance of the positive and negative syndrome scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.13.1825

10.1517/14656566.7.13.1825

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference